Radioactive 'Smart Bomb' targets Hard-to-Treat cancers in first human test
NCT ID NCT06824155
First seen Feb 15, 2026 · Last updated Jun 20, 2026 · Updated 25 times
Summary
This early-phase trial tests a new drug called 177Lu-RAD202, which is a radioactive antibody designed to seek out and deliver radiation directly to HER2-positive cancer cells. The study involves 30 adults with advanced solid tumors that have not responded to standard treatments. First, participants receive a small imaging dose to see where the drug goes in the body, then a treatment dose to check safety and find the best dose for future studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
GenesisCare Murdoch
RECRUITINGMurdoch, Western Australia, 6150, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Macquarie University Hospital
RECRUITINGMacquarie Park, New South Wales, 2109, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Nepean Hospital
RECRUITINGKingswood, New South Wales, 2747, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
St Vincents Hospital, Melbourne
NOT_YET_RECRUITINGFitzroy, Victoria, 3065, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Wollongong Hospital
RECRUITINGWollongong, New South Wales, 2500, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
177Lu-RAD202 (a radioactive antibody that targets HER2 on cancer cells)
What this could lead to
If it works, this could lead to a new targeted treatment option for people with advanced HER2-positive solid tumors that have stopped responding to other therapies.
What could go wrong
This is a very early (Phase 0/1) and small trial with only 30 participants. The main goal is safety and dosing, not yet effectiveness. There are risks from radiation exposure to healthy organs.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.